These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23964615)

  • 21. A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?
    San-Juan-Rodriguez A; Gellad WF; Shrank WH; Good CB; Hernandez I
    J Manag Care Spec Pharm; 2021 May; 27(5):565-573. PubMed ID: 33908276
    [No Abstract]   [Full Text] [Related]  

  • 22. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database.
    Howe A; Eyck LT; Dufour R; Shah N; Harrison DJ
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1236-44. PubMed ID: 25443517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescription drug costs and the generic dispensing ratio.
    Liberman JN; Roebuck MC
    J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Actuarial analysis of private payer administrative claims data for women with endometriosis.
    Mirkin D; Murphy-Barron C; Iwasaki K
    J Manag Care Pharm; 2007 Apr; 13(3):262-72. PubMed ID: 17407392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions.
    Doshi JA; Li P; Ladage VP; Pettit AR; Taylor EA
    Am J Manag Care; 2016 Mar; 22(3):188-97. PubMed ID: 27023024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
    J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacy benefit spending on oral chemotherapy drugs.
    Curtiss FR
    J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug super spender tsunami: An integrated medical and pharmacy benefits assessment.
    Starner CI; Bowen K; Gleason PP
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1200-1206. PubMed ID: 36282927
    [No Abstract]   [Full Text] [Related]  

  • 31. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.
    Atzinger CB; Guo JJ
    Am Health Drug Benefits; 2017 Feb; 10(1):27-36. PubMed ID: 28465766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
    Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
    J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
    Karaca-Mandic P; Joyce GF; Goldman DP; Laouri M
    Health Serv Res; 2010 Oct; 45(5 Pt 1):1227-50. PubMed ID: 20831715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003-14.
    Dusetzina SB
    Health Aff (Millwood); 2016 Jul; 35(7):1241-6. PubMed ID: 27385240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies.
    Alvarez E; Nair KV; Tan H; Rathi K; Gabler NB; Maiese EM; Deshpande C; Shao Q
    J Med Econ; 2023; 26(1):494-502. PubMed ID: 36970763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.